ES2368155T3 - Derivados de amidas cíclicas y su producción y uso en forma de agentes antitrombóticos. - Google Patents

Derivados de amidas cíclicas y su producción y uso en forma de agentes antitrombóticos. Download PDF

Info

Publication number
ES2368155T3
ES2368155T3 ES05743594T ES05743594T ES2368155T3 ES 2368155 T3 ES2368155 T3 ES 2368155T3 ES 05743594 T ES05743594 T ES 05743594T ES 05743594 T ES05743594 T ES 05743594T ES 2368155 T3 ES2368155 T3 ES 2368155T3
Authority
ES
Spain
Prior art keywords
acid
compound
chloronaphthalen
sulfonyl
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05743594T
Other languages
English (en)
Spanish (es)
Inventor
K. Kubo
Y. Imaeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2368155T3 publication Critical patent/ES2368155T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES05743594T 2004-05-21 2005-05-20 Derivados de amidas cíclicas y su producción y uso en forma de agentes antitrombóticos. Expired - Lifetime ES2368155T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004152000 2004-05-21
JP2004152000 2004-05-21

Publications (1)

Publication Number Publication Date
ES2368155T3 true ES2368155T3 (es) 2011-11-14

Family

ID=34968275

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05743594T Expired - Lifetime ES2368155T3 (es) 2004-05-21 2005-05-20 Derivados de amidas cíclicas y su producción y uso en forma de agentes antitrombóticos.

Country Status (26)

Country Link
US (4) US7745623B2 (enExample)
EP (2) EP2208726B1 (enExample)
JP (2) JP4129047B2 (enExample)
KR (1) KR101248637B1 (enExample)
CN (2) CN1989104B (enExample)
AT (1) ATE513813T1 (enExample)
AU (1) AU2005245298B2 (enExample)
BR (1) BRPI0511186A (enExample)
CA (1) CA2567506C (enExample)
CY (1) CY1111850T1 (enExample)
DK (1) DK1748985T3 (enExample)
ES (1) ES2368155T3 (enExample)
HR (1) HRP20110640T1 (enExample)
IL (1) IL178896A (enExample)
MX (1) MXPA06013243A (enExample)
MY (1) MY154461A (enExample)
NO (1) NO20065929L (enExample)
NZ (1) NZ550985A (enExample)
PH (1) PH12012501331A1 (enExample)
PL (1) PL1748985T3 (enExample)
PT (1) PT1748985E (enExample)
RS (1) RS51925B (enExample)
RU (1) RU2361861C2 (enExample)
SI (1) SI1748985T1 (enExample)
TW (1) TWI396686B (enExample)
WO (1) WO2005113504A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187023A1 (en) * 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
WO2004048363A1 (ja) * 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP1960433A2 (en) * 2005-11-28 2008-08-27 Zymogenetics, Inc. Il-21 receptor antagonists
EP2090300A4 (en) * 2006-11-30 2010-02-10 Takeda Pharmaceutical PREPARATION WITH DELAYED RELEASE
TW201014850A (en) 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
EP2371826A4 (en) 2008-12-29 2012-06-27 Takeda Pharmaceutical NEW CONNECTION WITH CONDENSED RINGS AND ITS USE
WO2010087467A1 (en) 2009-01-27 2010-08-05 Takeda Pharmaceutical Company Limited Delta-5-desaturase inhibitors
SG175794A1 (en) 2009-04-30 2011-12-29 Takeda Pharmaceutical Solid preparation
US20120172351A1 (en) 2009-06-09 2012-07-05 Nobuyuki Negoro Novel fused cyclic compound and use thereof
IN2012DN00954A (enExample) 2009-07-28 2015-04-10 Takeda Pharmaceutical
US8221489B2 (en) * 2009-08-20 2012-07-17 Stentys Device and method for treating a body lumen
EA021698B1 (ru) 2010-04-27 2015-08-31 Такеда Фармасьютикал Компани Лимитед Производные бициклических соединений и их применение в качестве ингибиторов acc
PH12012502468A1 (en) 2010-06-16 2015-05-08 Takeda Pharmaceuticals Co Crystal of amide compound
US9023858B2 (en) 2010-07-23 2015-05-05 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-d]pyrimidines as delta-5-desaturase inhibitors
EP2617726A4 (en) 2010-09-17 2014-05-14 Takeda Pharmaceutical DIABETES THERAPEUTIC
EP2649062B1 (en) 2010-11-30 2015-04-08 Takeda Pharmaceutical Company Limited Bicyclic compounds as inhibitors of acetyl-coa carboxylase (acc)
BR112013020634A2 (pt) 2011-02-17 2016-10-25 Takeda Pharmaceutical método para produzir uma forma opticamente ativa de um composto, sal, complexo de rutênio, composto, e, cristal
US9133129B2 (en) 2011-10-24 2015-09-15 Takeda Pharmaceutical Company Limited Bicyclic compound
JP6129850B2 (ja) 2012-01-12 2017-05-17 武田薬品工業株式会社 Ｍｃｈ受容体拮抗剤としてのベンゾイミダゾール誘導体
US9181186B2 (en) 2012-02-13 2015-11-10 Takeda Pharmaceutical Company Limited Aromatic ring compound
EP2816023A4 (en) 2012-02-13 2015-09-09 Takeda Pharmaceutical AROMATIC RING CONNECTION
WO2013122260A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
JP6106179B2 (ja) 2012-02-24 2017-03-29 武田薬品工業株式会社 芳香環化合物
CA2868713A1 (en) 2012-03-29 2013-10-03 Takeda Pharmaceutical Company Limited Aromatic ring compound
EP2848622A4 (en) 2012-05-10 2015-11-04 Takeda Pharmaceutical Aromatic ring compound
EP2848621A4 (en) 2012-05-10 2016-06-01 Takeda Pharmaceutical AROMATIC RING CONNECTION
AR092843A1 (es) 2012-06-05 2015-05-06 Takeda Pharmaceuticals Co Preparacion solida
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
CA2882879A1 (en) 2012-08-24 2014-02-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN103936763B (zh) * 2013-01-18 2017-10-31 中国科学院上海药物研究所 噁唑烷酮类化合物及其制备方法和用途
JP6247697B2 (ja) 2013-03-14 2017-12-13 武田薬品工業株式会社 スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用
WO2014165816A1 (en) 2013-04-05 2014-10-09 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
CA2917490A1 (en) 2013-07-09 2015-01-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6397410B2 (ja) 2013-08-09 2018-09-26 武田薬品工業株式会社 芳香環化合物
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP2017529401A (ja) * 2014-09-26 2017-10-05 チャーンジョウ インシュヨン ファーマシューティカル カンパニー，リミティド Ｎｓ４ｂ阻害剤としてのベンゾフラン類似体
BR122019023690B1 (pt) 2014-12-23 2020-07-28 Crossing Srl método para a produção industrial de 2-halo-4,6-dialcoxi-1,3,5-triazina e seu uso na presença de aminas
JPWO2018181847A1 (ja) 2017-03-31 2020-03-05 武田薬品工業株式会社 芳香環化合物
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
US11207312B2 (en) 2017-07-17 2021-12-28 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors and methods of use thereof
EA202092269A1 (ru) 2018-03-23 2020-12-14 Кармот Терапьютикс, Инк. Модуляторы сопряженных с g-белком рецепторов
JP6773938B2 (ja) 2018-08-27 2020-10-21 株式会社スコヒアファーマ 安息香酸エステル化合物
EP3856768A2 (en) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
EP3856339A1 (en) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
FI4097099T3 (fi) 2020-02-07 2024-07-30 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
AU2021241257A1 (en) 2020-03-25 2022-10-13 Takeda Pharmaceutical Company Limited QD dosing of GIP receptor agonist peptide compounds and uses thereof
AR121649A1 (es) 2020-03-25 2022-06-22 Takeda Pharmaceuticals Co Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos
PL4143183T3 (pl) 2020-04-29 2026-03-02 Gasherbrum Bio, Inc. Heterocykliczni agoniści glp-1
CN117980325A (zh) 2021-05-13 2024-05-03 卡莫特治疗学股份有限公司 G-蛋白偶联受体的调节剂
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
EP4496797A1 (en) 2022-03-21 2025-01-29 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2026501171A (ja) 2022-12-15 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド Ｇｌｐ－１アゴニスト活性を有する化合物の塩および固体形態
EP4638455A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4638440A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AU2024222719A1 (en) 2023-02-16 2025-08-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20250019389A1 (en) 2023-06-30 2025-01-16 Gasherbrum Bio, Inc. Heterocyclic agonists
WO2025015269A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Compounds, compositions, and methods
TW202521528A (zh) 2023-07-13 2025-06-01 美商雅空嘉閣生物公司 化合物、組合物及方法
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025154021A1 (en) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154020A1 (en) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss
WO2026041075A1 (en) 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US270488A (en) * 1883-01-09 Drilling apparatus
US2201270A (en) * 1936-04-17 1940-05-21 Mcintyre John Taylor Apparatus for allaying dust from rock drills
US2946565A (en) * 1953-06-16 1960-07-26 Jersey Prod Res Co Combination drilling and testing process
US2849214A (en) * 1954-09-02 1958-08-26 Gulf Research Development Co Borehole drilling apparatus for preventing lost circulation
US3497020A (en) * 1968-05-20 1970-02-24 Archer W Kammerer Jr System for reducing hydrostatic pressure on formations
JPS5011391B1 (enExample) * 1970-07-21 1975-04-30
SE355840B (enExample) * 1971-09-08 1973-05-07 Atlas Copco Ab
FR2228301B1 (enExample) 1973-05-03 1977-10-14 Ibm
US4147786A (en) * 1976-02-02 1979-04-03 Ciba-Geigy Corporation 1-Indolylalkyl-3-or 4-trimethyleneurido-piperidines
FI782133A7 (fi) 1977-07-08 1979-01-09 Ciba Geigy Ag Piperidino-propanoler och foerfarande foer deras framstaellning
EP0000485A1 (de) 1977-07-08 1979-02-07 Ciba-Geigy Ag Piperidino-propanole, ihre Herstellung und pharmazeutische Präparate die diese enthalten
US4329348A (en) * 1979-02-26 1982-05-11 Ciba-Geigy Corporation N-Oxacyclic-alkylpiperidines as psychostimulants
US4630691A (en) * 1983-05-19 1986-12-23 Hooper David W Annulus bypass peripheral nozzle jet pump pressure differential drilling tool and method for well drilling
US4534426A (en) * 1983-08-24 1985-08-13 Unique Oil Tools, Inc. Packer weighted and pressure differential method and apparatus for Big Hole drilling
US4567954A (en) * 1983-12-02 1986-02-04 Norton Christensen, Inc. Replaceable nozzles for insertion into a drilling bit formed by powder metallurgical techniques and a method for manufacturing the same
US4695575A (en) * 1984-11-13 1987-09-22 Janssen Pharmaceutica, N.V. 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
US5902272A (en) * 1992-01-07 1999-05-11 Arthrocare Corporation Planar ablation probe and method for electrosurgical cutting and ablation
HU218419B (hu) 1992-03-06 2000-08-28 E.R. Squibb And Sons, Inc. Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5355967A (en) * 1992-10-30 1994-10-18 Union Oil Company Of California Underbalance jet pump drilling method
GB9321557D0 (en) 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
GB9312806D0 (en) 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
GB9317104D0 (en) 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5456326A (en) * 1994-04-18 1995-10-10 Exxon Production Research Company Apparatus and method for installing open-ended tubular members axially into the earth
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
CA2200468A1 (en) 1994-10-27 1996-05-09 Wayne J. Thompson Muscarine antagonists
HUT77313A (hu) 1994-12-02 1998-03-30 Yamanouchi Pharmaceutical Co., Ltd. Amidino-naftil-származékok és sóik, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
GB9508786D0 (en) * 1995-04-29 1995-06-21 Zeneca Ltd Substituted heterocycles
DE69533991T2 (de) 1995-05-29 2006-04-13 Pfizer Inc. Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
US5612353A (en) 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
GB9602294D0 (en) 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
IL129877A (en) 1996-11-27 2004-08-31 Aventis Pharm Prod Inc A pharmaceutical preparation containing a component having an Xa antagonist activity and an antifouling agent
DE69835430T2 (de) 1997-05-30 2007-03-08 Takeda Pharmaceutical Co. Ltd. Sulfonamidderivate, ihre herstellung und verwendung
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
GB9715895D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
AU736112B2 (en) 1997-11-20 2001-07-26 Teijin Limited Biphenylamidine derivatives
MY116430A (en) 1997-11-21 2004-01-31 Schering Corp Substituted oximes as neurokinin antagonists
WO1999033805A1 (en) 1997-12-26 1999-07-08 Mochida Pharmaceutical Co., Ltd. Aromatic compounds having cyclic amino or salts thereof
CA2317017A1 (en) * 1998-02-05 1999-08-12 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, their production and use
SK15072000A3 (sk) * 1998-04-10 2001-08-06 Japan Tobacco Inc. Amidové zlúčeniny
US6129152A (en) * 1998-04-29 2000-10-10 Alpine Oil Services Inc. Rotating bop and method
GB9809349D0 (en) 1998-05-02 1998-07-01 Zeneca Ltd Heterocyclic derivatives
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
AU5196399A (en) 1998-08-11 2000-03-06 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
JP2000080046A (ja) * 1998-09-03 2000-03-21 Dai Ichi Seiyaku Co Ltd 多臓器障害の予防・治療剤
EP1115396A4 (en) 1998-09-25 2002-05-22 Sunol Molecular Corp PHARMACEUTICALLY ACTIVE COMPOUNDS, AND METHODS OF USE THEREOF
WO2000039114A2 (en) 1998-12-23 2000-07-06 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
US6204265B1 (en) * 1998-12-23 2001-03-20 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
EP1188755B1 (en) 1999-06-22 2006-05-03 Takeda Pharmaceutical Company Limited Acylhydrazine derivatives, process for preparing the same and use thereof
PL352862A1 (en) 1999-06-30 2003-09-08 Mochida Pharmaceutical Co, Ltd. Tricyclic compounds having spiro union
WO2001007436A2 (en) 1999-07-28 2001-02-01 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl compounds
AU7354900A (en) 1999-09-09 2001-04-10 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2001044172A1 (en) 1999-12-15 2001-06-21 Axys Pharmaceuticals, Inc. Salicylamides as serine protease and factor xa inhibitors
US6723091B2 (en) * 2000-02-22 2004-04-20 Gyrus Medical Limited Tissue resurfacing
US6629974B2 (en) * 2000-02-22 2003-10-07 Gyrus Medical Limited Tissue treatment method
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
US20030187023A1 (en) * 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
JP2002201178A (ja) * 2000-07-17 2002-07-16 Takeda Chem Ind Ltd スルホン誘導体、その製造法及び用途
US6511973B2 (en) * 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
EP1322610A2 (en) 2000-09-29 2003-07-02 Millennium Pharmaceuticals, Inc. PIPERAZINE BASED INHIBITORS OF FACTOR Xa
US6518538B2 (en) * 2000-10-18 2003-02-11 Mattioli Engineering Ltd. Method and apparatus for plasma skin resurfacing
FR2819511A1 (fr) 2001-01-18 2002-07-19 Servier Lab Nouveaux composes azepane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002068407A1 (en) 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole compound
AU2002322396A1 (en) 2001-07-26 2003-02-17 Eli Lilly And Company 1-glycinyl-4 (methylpiperidin-4-yl) piperazines and -piperridines as factor xa antagonists
US6877571B2 (en) * 2001-09-04 2005-04-12 Sunstone Corporation Down hole drilling assembly with independent jet pump
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
CN110894196A (zh) 2001-09-21 2020-03-20 百时美-施贵宝控股爱尔兰无限公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
EP1444219A1 (en) * 2001-10-12 2004-08-11 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
DE10155075A1 (de) 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
ATE454381T1 (de) * 2002-03-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Benzofuranderivat
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
DE10229070A1 (de) * 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
US20040006490A1 (en) 2002-07-08 2004-01-08 Gingrich Mark A. Prescription data exchange system
US20040077635A1 (en) * 2002-10-02 2004-04-22 Qiao Jennifer X. Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor Xa inhibitors
WO2004035579A1 (ja) 2002-10-15 2004-04-29 Takeda Pharmaceutical Company Limited イミダゾピリジン誘導体、その製造法および用途
WO2004048363A1 (ja) * 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
EP1597256A1 (en) * 2003-02-21 2005-11-23 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
US6899188B2 (en) * 2003-03-26 2005-05-31 Sunstone Corporation Down hole drilling assembly with concentric casing actuated jet pump
WO2005087266A1 (en) 2004-03-05 2005-09-22 Vddi Pharmaceuticals Combination therapy for inhibition of platelet aggregation
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US7988933B2 (en) 2006-09-01 2011-08-02 Siemens Healthcare Diagnostics Inc. Identification system for a clinical sample container
KR100906250B1 (ko) 2006-09-04 2009-07-07 주식회사 엘지화학 바인더로서 고중합도 폴리비닐알콜과 폴리비닐피롤리돈의혼합물을 포함하는 전극 합제 및 이를 포함하는 리튬이차전지

Also Published As

Publication number Publication date
WO2005113504A1 (en) 2005-12-01
KR101248637B1 (ko) 2013-03-28
EP2208726A1 (en) 2010-07-21
HRP20110640T1 (hr) 2011-10-31
IL178896A (en) 2012-07-31
NO20065929L (no) 2007-02-19
SI1748985T1 (sl) 2011-08-31
US8697865B2 (en) 2014-04-15
HK1100666A1 (en) 2007-09-28
US7745623B2 (en) 2010-06-29
CY1111850T1 (el) 2015-10-07
KR20070021205A (ko) 2007-02-22
US20080255352A1 (en) 2008-10-16
MXPA06013243A (es) 2007-02-08
PH12012501331A1 (en) 2013-06-17
PL1748985T3 (pl) 2011-11-30
US20080255362A1 (en) 2008-10-16
RU2006145449A (ru) 2008-06-27
EP2208726B1 (en) 2014-08-20
CA2567506C (en) 2013-06-18
DK1748985T3 (da) 2011-08-29
US20100160629A1 (en) 2010-06-24
EP1748985B1 (en) 2011-06-22
TWI396686B (zh) 2013-05-21
CN102093285A (zh) 2011-06-15
CN1989104B (zh) 2011-07-13
NZ550985A (en) 2011-02-25
JP4129047B2 (ja) 2008-07-30
PT1748985E (pt) 2011-07-29
AU2005245298A1 (en) 2005-12-01
CA2567506A1 (en) 2005-12-01
ATE513813T1 (de) 2011-07-15
JP2008163030A (ja) 2008-07-17
RS51925B (sr) 2012-02-29
AU2005245298B2 (en) 2011-04-07
JP2008500385A (ja) 2008-01-10
JP4362535B2 (ja) 2009-11-11
CN1989104A (zh) 2007-06-27
TW200600508A (en) 2006-01-01
US20070244118A1 (en) 2007-10-18
IL178896A0 (en) 2007-03-08
RU2361861C2 (ru) 2009-07-20
BRPI0511186A (pt) 2007-12-04
CN102093285B (zh) 2013-10-16
EP1748985A1 (en) 2007-02-07
MY154461A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
ES2368155T3 (es) Derivados de amidas cíclicas y su producción y uso en forma de agentes antitrombóticos.
ES2219894T3 (es) Derivados heterociclicos que inhiben el factor xa.
US6545054B1 (en) Alkenyl and alkynyl compounds as inhibitors of factor Xa
US9920034B2 (en) Crystalline forms of a factor XIa inhibitor
CN102464701B (zh) 一类新型化合物、其制备方法及用途
KR20170095845A (ko) 디히드로인돌리지논 유도체
ES2234133T3 (es) Derivados de (hetero)aril-sulfonamida, su preparacion y su uso como inhibidores del factor xa.
US20210395299A1 (en) Novel dipeptide compounds and uses thereof
JPWO2002083649A1 (ja) 新規イミダゾリジンジオン誘導体およびその医薬用途
JP5796872B2 (ja) 第Ｘａ因子阻害剤の結晶性塩
HK1100666B (en) Cyclic amide derivatives, and their production and use as antithrombotic agents
EP3778597B1 (en) Tetrahydroisoquinoline derivative, preparation method therefor and uses thereof
US7053112B2 (en) Imidazolidinedione analogs useful as anticoagulants and antithrombotics
JP3162587B2 (ja) 新規複素環誘導体及び血小板凝集阻害剤
WO2019144811A1 (zh) 四氢异喹啉类衍生物及其制备方法和用途
KR20000016164A (ko) 치환된 아미디노벤젠 유도체 및 이의 약제학적 조성물
JP2001011071A (ja) アミノアルキルスルホンアミド誘導体
WO2016189881A1 (en) Pharmaceutical composition for treating cerebral infarction
HK40031655A (en) Tetrahydroisoquinoline derivative, preparation method therefor and uses thereof
WO2013151719A2 (en) Fluorinated oxazolidinone derivatives
HK40031655B (zh) 四氢异喹啉类衍生物及其制备方法和用途
JP2004123538A (ja) ジフェニルチアゾリジンジオン誘導体およびその医薬用途
JPWO2000031045A1 (ja) ナフタレン誘導体
JPWO2001077082A1 (ja) ナフタレン誘導体
JPWO2002048096A1 (ja) ヒドラゾン誘導体およびその医薬用途